Y-mAbs Therapeutics Stock (NASDAQ: YMAB) stock price, news, charts, stock research, profile.
Open | $16.480 |
Close | $16.260 |
Volume / Avg. | 270.332K / 401.265K |
Day Range | 15.935 - 16.500 |
52 Wk Range | 2.960 - 20.900 |
Market Cap | $711.816M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 54 |
Short Interest | - |
Days to Cover | 5.24 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Y-mAbs Therapeutics (NASDAQ: YMAB) through any online brokerage.
Other companies in Y-mAbs Therapeutics’s space includes: Cogent Biosciences (NASDAQ:COGT), Korro Bio (NASDAQ:KRRO), Pharming (NASDAQ:PHAR), Cullinan Oncology (NASDAQ:CGEM) and Neurogene (NASDAQ:NGNE).
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by HC Wainwright & Co. on Wednesday, March 6, 2024. The analyst firm set a price target for 22.00 expecting YMAB to rise to within 12 months (a possible 35.30% upside). 18 analyst firms have reported ratings in the last year.
The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $16.26 last updated March 28, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Y-mAbs Therapeutics.
Y-mAbs Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Y-mAbs Therapeutics.
Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.